Atlas Trials

A Study of TQB2450 Injection and Anlotinib Hydrochloride Capsules to Treat Triple Negative Breast Cancer (TNBC)

Clinical trial NCT03855358 · UNKNOWN

Trial details

NCT number
NCT03855358
Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Status
UNKNOWN
Phase
Phase 1
Study type
INTERVENTIONAL
Triple Negative Breast Cancer (TNBC)
Start date
2019-05-09
Primary completion
2020-06-30
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.